InspireMD (NYSE:NSPR) Research Coverage Started at Lake Street Capital

Lake Street Capital began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $5.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. StockNews.com assumed coverage on InspireMD in a research report on Wednesday, December 4th. They set a “sell” rating on the stock. Piper Sandler restated an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Price Performance

Shares of NYSE NSPR opened at $2.95 on Wednesday. The stock has a market capitalization of $76.94 million, a P/E ratio of -3.93 and a beta of 0.98. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The company has a 50-day moving average price of $2.66 and a 200-day moving average price of $2.68.

InspireMD (NYSE:NSPR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. As a group, equities research analysts anticipate that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC acquired a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned approximately 0.42% of InspireMD at the end of the most recent quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.